JP2005505256A5 - - Google Patents

Download PDF

Info

Publication number
JP2005505256A5
JP2005505256A5 JP2003502040A JP2003502040A JP2005505256A5 JP 2005505256 A5 JP2005505256 A5 JP 2005505256A5 JP 2003502040 A JP2003502040 A JP 2003502040A JP 2003502040 A JP2003502040 A JP 2003502040A JP 2005505256 A5 JP2005505256 A5 JP 2005505256A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
antigen
binding fragment
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003502040A
Other languages
English (en)
Japanese (ja)
Other versions
JP4527394B2 (ja
JP2005505256A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/017402 external-priority patent/WO2002098920A1/en
Publication of JP2005505256A publication Critical patent/JP2005505256A/ja
Publication of JP2005505256A5 publication Critical patent/JP2005505256A5/ja
Application granted granted Critical
Publication of JP4527394B2 publication Critical patent/JP4527394B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003502040A 2001-06-01 2002-05-31 Ｋｉｍ−１の分断を阻害するための分子および方法 Expired - Fee Related JP4527394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29544901P 2001-06-01 2001-06-01
US29590701P 2001-06-04 2001-06-04
PCT/US2002/017402 WO2002098920A1 (en) 2001-06-01 2002-05-31 Molecules and methods for inhibiting shedding of kim-1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010068988A Division JP2010150291A (ja) 2001-06-01 2010-03-24 Ｋｉｍ−１の分断を阻害するための分子および方法

Publications (3)

Publication Number Publication Date
JP2005505256A JP2005505256A (ja) 2005-02-24
JP2005505256A5 true JP2005505256A5 (enExample) 2006-01-05
JP4527394B2 JP4527394B2 (ja) 2010-08-18

Family

ID=26969139

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003502040A Expired - Fee Related JP4527394B2 (ja) 2001-06-01 2002-05-31 Ｋｉｍ−１の分断を阻害するための分子および方法
JP2010068988A Withdrawn JP2010150291A (ja) 2001-06-01 2010-03-24 Ｋｉｍ−１の分断を阻害するための分子および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010068988A Withdrawn JP2010150291A (ja) 2001-06-01 2010-03-24 Ｋｉｍ−１の分断を阻害するための分子および方法

Country Status (10)

Country Link
US (3) US7041290B2 (enExample)
EP (1) EP1401869B1 (enExample)
JP (2) JP4527394B2 (enExample)
AT (1) ATE382060T1 (enExample)
AU (1) AU2002305785B2 (enExample)
CA (1) CA2448427C (enExample)
DE (1) DE60224275T2 (enExample)
DK (1) DK1401869T3 (enExample)
NZ (1) NZ530457A (enExample)
WO (1) WO2002098920A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4602482B2 (ja) * 1996-05-24 2010-12-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組織再生のモジュレーター
JP2004500879A (ja) * 2000-06-16 2004-01-15 バイオジェン　インコーポレイテッド 腎の調節エレメントおよびそれらの使用方法
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
AU2003228336B2 (en) * 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2013205381B2 (en) * 2002-03-19 2016-04-14 Celldex Therapeutics, Inc. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2512138C (en) * 2002-12-30 2013-07-16 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
AU2013242840B2 (en) * 2003-03-19 2017-01-19 Amgen Fremont Inc. Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof
CA2519528C (en) * 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
EP1532984A1 (en) * 2003-11-19 2005-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
EP1865985B1 (en) 2005-03-02 2010-08-25 Biogen Idec MA Inc. Kim-1 antibodies for treatment of th2-mediated conditions
EP1957115B8 (en) 2005-11-10 2014-03-05 Celldex Therapeutics, Inc. Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
JP6223659B2 (ja) 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
US9476868B2 (en) 2009-12-23 2016-10-25 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a canine
JP6012473B2 (ja) 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
TW201244737A (en) 2011-02-03 2012-11-16 Alexion Pharma Inc Use of an anti-CD200 antibody for prolonging the survival of allografts
US20150110792A1 (en) * 2011-11-22 2015-04-23 Biogen Idec Ma Inc. ANTI-TIM-1 Antibodies And Uses Thereof
WO2015023836A1 (en) * 2013-08-16 2015-02-19 The Brigham And Women's Hospital, Inc. Kim-1 as a therapeutic target in conditions associated with kidney fibrosis
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
US11541076B2 (en) 2017-01-13 2023-01-03 Celdara Medical, Llc Chimeric antigen receptors targeting TIM-1
US11820728B2 (en) 2017-04-28 2023-11-21 Acuitas Therapeutics, Inc. Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3852911B1 (en) 2018-09-21 2025-01-22 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
PL3908568T3 (pl) 2019-01-11 2024-12-02 Acuitas Therapeutics, Inc. Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych
KR20230051172A (ko) 2020-07-16 2023-04-17 아퀴타스 테라퓨틱스 인크. 지질 나노 입자에 사용하기 위한 양이온성 지질
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622861A (en) 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
JP4602482B2 (ja) * 1996-05-24 2010-12-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 組織再生のモジュレーター
JP2004500879A (ja) * 2000-06-16 2004-01-15 バイオジェン　インコーポレイテッド 腎の調節エレメントおよびそれらの使用方法
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
JP4572276B2 (ja) * 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法
US7838220B2 (en) * 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
CA2459219A1 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7687454B2 (en) * 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
JP4694128B2 (ja) * 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
AU2003228336B2 (en) 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
CA2519528C (en) 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
US20050119210A1 (en) 2003-05-20 2005-06-02 Xiaobing Be Compositions and methods for diagnosing and treating cancers

Similar Documents

Publication Publication Date Title
JP2005520566A5 (enExample)
JP2022120070A (ja) 抗ｃｄ７１抗体、活性化可能抗ｃｄ７１抗体、およびその使用方法
JP2023081303A5 (enExample)
CA2928895C (en) Antibodies against ccr9 and applications thereof
JP2010535713A5 (enExample)
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
JP2004534020A5 (enExample)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2008529497A5 (enExample)
JP2025183307A5 (enExample)
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
JP2010513303A5 (enExample)
CA2595610A1 (en) Antibodies directed to angiopoietin-2 and uses thereof
HK1221153A1 (zh) 抗体-药物缀合物
JP2012532851A5 (enExample)
RU2013125306A (ru) Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование
JP2009197002A5 (enExample)
RU2010141584A (ru) Антитело против csf-1r
RU2011110405A (ru) Агенты, связывающие рецептор frizzled и их применение
JP2010533498A5 (enExample)
JP2004518624A5 (enExample)
JP2010508847A5 (enExample)
JP2014502955A5 (enExample)
CN108452320B (zh) 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途
JP2024525870A5 (enExample)